First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The groups spend big on Terns and Arcellx.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The group wants to improve on its own Welireg in a new phase 3 trial.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
After a delay, the Alpha-3 study faces an April futility analysis.
